Ketamine + Placebo
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Dec 22, 2015 → May 7, 2018
NCT ID
NCT02611921About Ketamine + Placebo
Ketamine + Placebo is a phase 1 stage product being developed by Roivant Sciences for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02611921. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02611921 | Phase 1 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder